-
Neurotrope's Phase 2 Drug To Treat Alzheimer's Doesn't Clear Threshold For Statistical Significance
Monday, May 1, 2017 - 6:41am | 1250Read More...After hearing Neurotrope Inc (NASDAQ: NTRP) would announce results of its Phase 2 study of potential Alzheimer’s Disease (AD) treatment Bryostatin-1, biotech investors have waited with baited breath through the weekend. On Monday, Neurotrope reported positive top-line results from its Phase 2...
-
Alzheimer's Pipeline In Focus At Oppenheimer Conference As Neurotrope's Trial Results Approach
Wednesday, March 22, 2017 - 2:10pm | 901Read More...Neurotrope Inc (OTC: NTRP) was caught with other biotechs in a harsh, broad market selloff Tuesday that saw all major indices close lower. The company focuses on developing therapies for neurodegenerative diseases, most notably Alzheimer's Disease. Neurotrope has this in common with Anavex Life...
-
Neurotrope: A Company You Never Heard Of Might Have The Biggest Drug Ever In Biotech
Friday, January 27, 2017 - 5:38pm | 535Read More...Neurotrope Inc (OTC: NTRP), a clinical stage biopharmaceutical company, may have found through its drug Bryostatin a unique solution to addressing Alzheimer's, one of the last major diseases with no cure. Benzinga recently spoke with CEO Dr. Susanne Wilke, ahead of her appearance at the...
